• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Advances on Epstein-Barr virus related post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation].[异基因造血干细胞移植后爱泼斯坦-巴尔病毒相关移植后淋巴增殖性疾病的研究进展]
Zhonghua Xue Ye Xue Za Zhi. 2017 Sep 14;38(9):817-821. doi: 10.3760/cma.j.issn.0253-2727.2017.09.020.
2
Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后与 EBV 相关的移植后淋巴增殖性疾病的危险因素。
Haematologica. 2014 Feb;99(2):346-52. doi: 10.3324/haematol.2013.087338. Epub 2013 Sep 20.
3
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.异基因造血干细胞移植后患者的爱泼斯坦-巴尔病毒感染及移植后淋巴增殖性疾病的管理：第六届欧洲白血病感染会议（ECIL-6）指南
Haematologica. 2016 Jul;101(7):803-11. doi: 10.3324/haematol.2016.144428.
4
Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植后 EBV 相关移植后淋巴增殖性疾病的中枢神经系统受累。
Transplant Cell Ther. 2021 Mar;27(3):261.e1-261.e7. doi: 10.1016/j.jtct.2020.12.019. Epub 2020 Dec 22.
5
Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植中与爱泼斯坦-巴尔病毒相关的移植后淋巴细胞增殖性疾病预防策略
Rev Med Virol. 2020 Jul;30(4):e2108. doi: 10.1002/rmv.2108. Epub 2020 Apr 17.
6
Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.单剂量利妥昔单抗对爱泼斯坦-巴尔病毒感染进行成功的抢先治疗，以预防儿童造血干细胞移植后移植后淋巴细胞增殖性疾病。
Transpl Infect Dis. 2019 Dec;21(6):e13182. doi: 10.1111/tid.13182. Epub 2019 Oct 15.
7
Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.抗胸腺细胞球蛋白预处理的异基因造血细胞移植后移植后淋巴增殖性疾病中 EBV 的动力学。
Transpl Infect Dis. 2021 Oct;23(5):e13719. doi: 10.1111/tid.13719. Epub 2021 Sep 12.
8
Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.血液恶性肿瘤患者行单倍体相合与同胞相合 PBSCT 后 EBV-DNA 血症和移植后淋巴增殖性疾病的危险因素和临床结局。
Ann Hematol. 2019 Sep;98(9):2163-2177. doi: 10.1007/s00277-019-03742-7. Epub 2019 Jun 26.
9
Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation.造血干细胞移植后发生移植后淋巴组织增生性疾病的危险因素和预测评分系统。
Biol Blood Marrow Transplant. 2019 Jul;25(7):1441-1449. doi: 10.1016/j.bbmt.2019.02.016. Epub 2019 Feb 20.
10
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.塔布雷塞莱珠单抗治疗利妥昔单抗或利妥昔单抗联合化疗失败后发生 EBV 阳性移植后淋巴增殖性疾病的异基因造血干细胞或实体器官移植受者（ALLELE）：一项 3 期、多中心、开放标签试验。
Lancet Oncol. 2024 Mar;25(3):376-387. doi: 10.1016/S1470-2045(23)00649-6. Epub 2024 Jan 31.

本文引用的文献

1
Risk Factors for and the Clinical Impact of Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Recipients of TCR-α/β- and CD19-Depleted Grafts.TCR-α/β和CD19去除移植物的儿科受者中巨细胞病毒和EB病毒感染的危险因素及其临床影响
Biol Blood Marrow Transplant. 2017 Mar;23(3):483-490. doi: 10.1016/j.bbmt.2016.12.635. Epub 2016 Dec 27.
2
Epstein-Barr Virus: Diseases Linked to Infection and Transformation.爱泼斯坦-巴尔病毒：与感染和转化相关的疾病
Front Microbiol. 2016 Oct 25;7:1602. doi: 10.3389/fmicb.2016.01602. eCollection 2016.
3
Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.造血干细胞移植后爱泼斯坦-巴尔病毒载量的动态变化及抢先使用利妥昔单抗治疗的效果
Transpl Infect Dis. 2016 Dec;18(6):889-895. doi: 10.1111/tid.12618. Epub 2016 Nov 24.
4
Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation.基于利妥昔单抗的治疗，随后进行过继性细胞免疫治疗，用于经活检证实的异基因造血干细胞移植受者的EB病毒相关移植后淋巴增殖性疾病。
Oncoimmunology. 2016 Mar 10;5(5):e1139274. doi: 10.1080/2162402X.2016.1139274. eCollection 2016 May.
5
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.异基因造血干细胞移植后患者的爱泼斯坦-巴尔病毒感染及移植后淋巴增殖性疾病的管理：第六届欧洲白血病感染会议（ECIL-6）指南
Haematologica. 2016 Jul;101(7):803-11. doi: 10.3324/haematol.2016.144428.
6
Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT.在接受过利妥昔单抗治疗的阿仑单抗预处理的异基因造血干细胞移植受者中，EB病毒重新激活的风险大幅降低。
Bone Marrow Transplant. 2016 Jun;51(6):825-32. doi: 10.1038/bmt.2016.19. Epub 2016 Feb 22.
7
Epstein- Barr Virus: Clinical and Epidemiological Revisits and Genetic Basis of Oncogenesis.爱泼斯坦-巴尔病毒：临床与流行病学再探讨及肿瘤发生的遗传基础
Open Virol J. 2015 Nov 3;9:7-28. doi: 10.2174/1874357901509010007. eCollection 2015.
8
The value of 18F-FDG PET in pediatric patients with post-transplant lymphoproliferative disorder at initial diagnosis.18F-FDG PET在移植后淋巴细胞增生性疾病初诊儿科患者中的价值。
Pediatr Transplant. 2015 Dec;19(8):932-9. doi: 10.1111/petr.12611. Epub 2015 Oct 30.
9
Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes.非处理的人类白细胞抗原半相合造血干细胞移植后与爱泼斯坦-巴尔病毒相关的移植后淋巴细胞增殖性疾病：发病率、危险因素、治疗及临床结局
Biol Blood Marrow Transplant. 2015 Dec;21(12):2185-2191. doi: 10.1016/j.bbmt.2015.07.035. Epub 2015 Aug 5.
10
Successful treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disease with central nervous system involvement following allogeneic haematopoietic stem cell transplantation - a case study.异基因造血干细胞移植后成功治疗累及中枢神经系统的爱泼斯坦-巴尔病毒相关移植后淋巴增殖性疾病——病例报告
Cent Eur J Immunol. 2015;40(1):122-5. doi: 10.5114/ceji.2015.50845. Epub 2015 Apr 22.

[Advances on Epstein-Barr virus related post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation].

作者信息

Liu L, Feng S Z

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2017 Sep 14;38(9):817-821. doi: 10.3760/cma.j.issn.0253-2727.2017.09.020.

DOI:10.3760/cma.j.issn.0253-2727.2017.09.020
PMID:29081206
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7348362/
Abstract
摘要